Year One After Selling to PE: What the Physicians Actually Say

The Deal

The pitch usually arrives when the practice is under some combination of operational stress, competitive pressure, and physician fatigue. The managing partner is tired of running the business. The group has been approached by a health system and is worried about what happens if they say no. A competitor in the market just sold, and the physicians are watching that group expand with capital they do not have.

The PE firm offers a compelling multiple. The structure is typically a combination of cash at close and rollover equity in the platform, with the promise that the rollover will be worth significantly more when the platform sells in three to five years. The physicians retain clinical autonomy. The administrative burden transfers to the platform. The managing partner gets to stop being the de facto COO.

For a group that has been grinding through operational challenges for years, this can feel like relief.

What Year One Actually Looks Like

The first few months after close are often genuinely positive. The cash is in the bank. The platform team is attentive and responsive. The integration process is managed carefully because the PE firm knows that physician defection in the first year is the primary risk to their investment thesis. The physicians are treated as partners.

By month four or five, the integration begins in earnest. This is when the experience starts to diverge from the letter of intent.

The first thing physicians notice is the reporting. The practice now has a new set of metrics it is required to track and report to the platform. Some of these metrics are familiar. Others are new, and the physicians quickly realize that the platform's definition of a well-performing practice is not identical to their own. Productivity targets that seemed reasonable in the abstract become less reasonable when they are applied to the specific patient population and payer mix of the practice.

The second thing they notice is the vendor consolidation. The platform has preferred vendors for everything: EHR, billing, supplies, staffing agencies, malpractice insurance. The contracts with those vendors were negotiated at scale across the platform, and the economics are presented as favorable. In some cases they are. In others, the practice is paying more for a service that is less tailored to its specific needs than what it had before, and the physicians have no leverage to change it.

The third thing they notice is the pace of decision-making. In a physician-owned practice, decisions get made by the partners. The process can be slow and contentious, but it is local. In a PE-backed platform, decisions that affect the practice are made at the platform level, by people who are managing a portfolio of practices and optimizing for the portfolio, not for any individual group. A request to hire a new provider, add a service line, or make a capital investment goes into a queue and comes back with a decision that may or may not reflect the local context.

The Clinical Autonomy Question

The letter of intent almost always says the physicians retain clinical autonomy. In year one, this is generally true. The platform is not telling physicians how to practice medicine.

But clinical autonomy and operational autonomy are different things, and the line between them is blurrier than the letter of intent suggests. When the platform sets productivity targets that require a certain number of visits per day, that is not technically a clinical decision. But it shapes the clinical environment in ways that physicians feel. When the platform standardizes the EHR workflow across all practices in the portfolio, that is not technically a clinical decision. But it changes how physicians document and interact with patients.

By the end of year one, most physicians in PE-backed practices have a more nuanced view of what clinical autonomy means in practice than they did at close. The autonomy is real but bounded, and the bounds are set by people who are primarily accountable to investors, not to patients or physicians.

What the Physicians Say

The honest conversations happen in private. Physicians who have sold to PE are generally reluctant to say publicly that they regret it, for reasons that are understandable: the deal is done, the rollover equity is still outstanding, and public criticism of the platform creates professional and financial risk.

But in private, the themes are consistent.

The most common one is a sense of loss of agency that is hard to articulate precisely. The physicians are not being mistreated. The platform is not violating the terms of the agreement. But the feeling of owning something, of being accountable for it and in control of it, is gone. The practice is now a unit in a portfolio. The physicians are employees with equity, which is a different thing than being owners.

The second theme is surprise at how much the administrative burden persists. The pitch was that the platform would handle the operational complexity. In practice, the physicians are still dealing with operational problems, but now they are dealing with them through a layer of platform administration that adds process without always adding resolution. The problems are the same. The path to solving them is longer.

The third theme is a quiet calculation about the rollover equity. The physicians were told the platform would sell in three to five years at a higher multiple. By the end of year one, most of them have started to think more carefully about what that actually means: that their financial outcome depends on the performance of a portfolio they do not control, managed by a firm whose interests are not identical to theirs, on a timeline that may or may not align with their own plans.

What This Means for Practices That Have Not Sold

The physicians who are most candid about year one are often the ones who are most useful to practices that are still considering a sale. The message is not that selling to PE is always the wrong decision. For some practices, in some circumstances, it is the right one.

The message is that the decision deserves more scrutiny than the pitch typically receives. The multiple is real. The operational relief is partially real. The clinical autonomy is partially real. The rollover equity is a bet on a future that is not in the physicians' control.

Practices that are considering a sale because they are operationally exhausted should ask a different question first: is the exhaustion coming from the business being fundamentally unviable, or from the business being run without the operational infrastructure it needs? Those are different problems with different solutions. The first might warrant a sale. The second almost certainly does not.